ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1735

An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry

Christian Geier1, Haani Qudsi2, Jihad BenGabr1, Robert Winchester3 and Andras Perl4, 1SUNY Upstate Medical University, Syracuse, NY, 2Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, 3Columbia University, New York, NY, 4SUNY, Syracuse, NY

Meeting: ACR Convergence 2023

Keywords: autoimmune diseases, Dendritic cells, Inflammation, neutrophils, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found that RA blood contains ‘unorthodox’ DRhi immune cells (non-lymphoid cells that do not conform to bona fide definitions of monocytesnor dendritic cells).The purpose of the study was to determine whether DRhi immune cells expressing granulocyte associated molecules (CD15, CCR3)contribute to these alterations of the DRhi pool in RA.

Methods: We studied RA patients (n=12) satisfying the 2010 ACR classification criteria and matched healthy donors by flow cytometry. PBMC and other low-density cells were isolated from blood by Ficoll density gradient centrifugation. To gate non-lymphoid DRhi cells we excluded lymphocytes and non-viable cells based onforward and side scatter, CD3/CD19 dump and viability gates (Fig. 1A). We quantified the contribution of CD15+ cells to the non-lymphoid DRhi pool and their expression (MFI) of co-stimulatory and co-inhibitory molecules. We used t-SNE on index patients (debilitating polyarticular synovitis)to clarify the higher-dimensional structure of the CD15positive DRhi subpopulation followed by bi-axial gating to validate anyt-SNE guided observation and quantify distinctive features of DRhiCD15+. Kruskal-Wallis testing with a threshold of p< 0.05 was performed to assess for significant differences.

Results: In RA we found a non-lymphoid DRhi CD15+ population that was virtually absent in healthy donors (HD)(RA 0.98% vs. HD 0.05% of non-lymphoid DRhi; p<0.01, Fig. 1B, 2B); these cells have near uniform CD16 co-expression (Fig 1A, gated in last plot).DRhi CD15+ showed—as expected from granulocytic cells — high side scatter but differed from granulocytes by a striking co-expression of plasma cytoid (pDC) marker CD303 (Fig. 2A, B; circled);CD123, highly expressed by pDC, was not expressed. Given the shared features with both granulocytes and pDC we refer to this population as DRhi ‘Hybrid’ cells. DRhi Hybrids formed a separate cluster in RA which, along with CD303, co-expressed CD83 and CD275 (ICOS-L) (Fig. 2A, circled population).Lack of CD45RAseparatedCD303+DRhi Hybrids from their apparent bone fide CD303+ CD45RAint pDC counterparts (Fig. 3A and B, p< 0.001), CD45RA expression of RA pDC and HD pDC did not differ (Fig 3B, left). CCR3 expression within non-lymphoid DRhi was negligible (not shown).

Conclusion: RA blood contains DRhiCD15+ cells, contributing to the non-lymphoid DRhi pool in RA. Because these low-density cells share features with both granulocytes and pDCs we refer to them as DRhi Hybrids; their expression of CD303 challenges the notion that this molecule is specific for plasmacytoid DC. Co-expression of CD83, CD275 suggests an inflammatory potential whereas their lack of CD45RA (as opposed to CD303+pDCs) is reminiscent of the altered CD45RA expression we found previously in a DC2-like DRhi subset. Joint expression of CD303 and DR suggests that DRhi Hybrids maybe functionally involved in the capture and ultimate presentation of RA self-peptides to T lymphocytes. These apparently new DRhi Hybrids and other unorthodox DRhi populations are potential treatment targets in RA.

Supporting image 1

Flow cytometry and quantification of non-lymphoid DRhiCD15+ in RA. A) Gating strategy, patient with severe RA shown. B) DRhiCD15+ quantification in healthy donors (HD; blue) and RA (orange) and as percentage of non-lymphoid DRhi, logarithmic scale. Kruskal-Wallis Test ** p=0.0063

Supporting image 2

Non-lymphoid DRhiCD15+CD16+. A) t-SNE from an RA patient with debilitating polyarthritis population (red circle and arrow) highlighting co-expression of CD303, CD83, CD275; lack of CD123. Red: high expression. Blue: low expression. B) Bi-axial gating of DRhiCD15+CD16+ and pDC reference populations. CD303 x-axis, CD123 y-axis. Left plot: healthy donor Right plot: RA patient.

Supporting image 3

Comparison of CD303+ DRhiHybrids with CD303+ plasmacytoid DC. A) CD45RA and CD303 expression in healthy donor plasmacytoid DC (left; purple) and RA (with presence of DRhi hybrids) B) Quantification of CD45RA MFI of CD303+ pDC from RA (orange) and HD (blue) and CD303+ DRhi Hybrids. logarithmic scale. Kruskal-Wallis Test **** p=0.0008324


Disclosures: C. Geier: None; H. Qudsi: None; J. BenGabr: None; R. Winchester: None; A. Perl: None.

To cite this abstract in AMA style:

Geier C, Qudsi H, BenGabr J, Winchester R, Perl A. An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/an-unorthodox-hla-drhicd15-hybrid-population-in-rheumatoid-arthritis-characterized-using-spectral-cytometry/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-unorthodox-hla-drhicd15-hybrid-population-in-rheumatoid-arthritis-characterized-using-spectral-cytometry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology